These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11315354)

  • 1. High-dose intravenous immunoglobulins for lupus nephritis--a salvage immunomodulation.
    Rauova L; Lukac J; Levy Y; Rovensky J; Shoenfeld Y
    Lupus; 2001; 10(3):209-13. PubMed ID: 11315354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus.
    Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2006 Feb; 5(2):153-5. PubMed ID: 16431350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG.
    Silvestris F; D'Amore O; Cafforio P; Savino L; Dammacco F
    Clin Exp Immunol; 1996 May; 104 Suppl 1():91-7. PubMed ID: 8625551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.
    Toubi E; Kessel A; Shoenfeld Y
    Hum Immunol; 2005 Apr; 66(4):395-402. PubMed ID: 15866703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immunoglobulin therapy and systemic lupus erythematosus.
    Zandman-Goddard G; Levy Y; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):219-28. PubMed ID: 16391397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of high-dose intravenous immunoglobulins in the therapy of connectivitis: preliminary experience in 5 cases].
    De Vita S; D'Ascanio A; Bombardieri S
    Recenti Prog Med; 1991 Nov; 82(11):603-6. PubMed ID: 1763234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of lupus crisis with IgIV].
    Vázquez García MJ; Olalde Carmona R; Juárez JA; Escárcega Barbosa D
    Rev Alerg Mex; 1998; 45(6):143-6. PubMed ID: 9951325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apheresis in lupus nephritis.
    Mistry-Burchardi N; Schönermarck U; Samtleben W
    Ther Apher; 2001 Jun; 5(3):161-70. PubMed ID: 11467751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lupus nephritis associated with common variable immunodeficiency: favourable outcome with intravenous immunoglobulin treatment].
    Geneviève M; Bonnet F; Michaux C; Geffroy CE; Vandenhende MA; Combe C; Morlat P
    Rev Med Interne; 2012 Jun; 33(6):e31-3. PubMed ID: 22560369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis.
    Spertini F; Leimgruber A; Morel B; Khazaeli MB; Yamamoto K; Dayer JM; Weisbart RH; Lee ML
    J Rheumatol; 1999 Dec; 26(12):2602-8. PubMed ID: 10606369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the treatment of lupus nephritis.
    Zimmerman R; Radhakrishnan J; Valeri A; Appel G
    Annu Rev Med; 2001; 52():63-78. PubMed ID: 11160768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose intravenous immunoglobulins: a new step in the treatment of systemic lupus erythematosus.
    Rauova L; Rovensky J; Shoenfeld Y
    Isr Med Assoc J; 2000 May; 2(5):388-92. PubMed ID: 10892397
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases.
    Winder A; Molad Y; Ostfeld I; Kenet G; Pinkhas J; Sidi Y
    J Rheumatol; 1993 Mar; 20(3):495-8. PubMed ID: 8478856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus].
    Francioni C; Fioravanti A; Gelli R; Megale F; Marcolongo R
    Recenti Prog Med; 1993 Oct; 84(10):679-86. PubMed ID: 8235034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis.
    Niu Z; Zhang P; Tong Y
    Int J Rheum Dis; 2015 Jan; 18(1):17-28. PubMed ID: 25546242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies in lupus - focus on nephritis.
    Cordeiro AC; Isenberg DA
    Acta Reumatol Port; 2008; 33(2):157-69. PubMed ID: 18604181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [High dose intravenous immunoglobulins in treating systemic lupus erythematosus-associated thrombocytopenia].
    Zhang X; Dong Y; Tang F; Zhang F; Li H
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):82-4. PubMed ID: 12903501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus.
    Racz Z; Nagy E; Rosivall L; Szebeni J; Hamar P
    Lupus; 2010 Apr; 19(5):599-612. PubMed ID: 20167630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Th1/Th2 balance of SLE patients with lupus nephritis.
    Nakashima H; Akahoshi M; Masutani K
    Rinsho Byori; 2006 Jul; 54(7):706-13. PubMed ID: 16913661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of rapidly progressive lupus nephritis associated MPO-ANCA with tacrolimus.
    Morimoto S; Watanabe T; Lee S; Amano H; Kanamaru Y; Ohsawa I; Tomino Y; Takasaki Y
    Mod Rheumatol; 2010 Jun; 20(3):291-4. PubMed ID: 20082110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.